Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasis - 15/10/15
Author Contributions: Dr Chiesa Fuxench had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Drs Chiesa Fuxench and Gelfand. Acquisition of data: Drs Gelfand, Callis Duffin, and Van Voorhees. Analysis and interpretation of data: Drs Chiesa Fuxench and Gelfand. Drafting of the manuscript: Drs Chiesa Fuxench and Gelfand. Critical revision of the manuscript for important intellectual content: Drs Chiesa Fuxench, Callis Duffin, Siegel, Van Voorhees, and Gelfand. Statistical analysis: Dr Chiesa Fuxench. Obtained funding: Drs Gelfand and Callis Duffin. Administrative, technical, or material support: None. Study supervision: Dr Gelfand. |
|
Funding sources: This study was supported by grant RC1-AR058204 and K24-AR064310 36 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (Dr Gelfand), National Psoriasis Foundation Research Grant (Dr Chiesa Fuxench), and Training Grant 5T32GM075766-09 from the National Institutes of Health (Dr Chiesa Fuxench). The sponsors had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; in the preparation, review, or approval of the manuscript; or in the decision to submit the manuscript for publication. |
|
Conflicts of interest: Dr Callis Duffin was an investigator, consultant, and/or speaker for AbbVie, Amgen, ApoPharma, Bristol-Myers Squibb, Celgene, Eli Lilly, Genzyme, Incyte, Janssen Biologics/Centocor, NovoNordisk, Pfizer, and Wyeth, receiving honoraria and/or salary; served on the advisory board of Amgen; and received residency/fellowship program funding from AbbVie and Amgen. Dr Gelfand served as a consultant for AbbVie, Amgen, Celgene, Eli Lilly, Merck, Janssen Biologics (formerly Centocor), Novartis, and Pfizer, receiving honoraria; had grants or has pending grants from AbbVie, Amgen, Eli Lilly, Genentech, Novartis, and Pfizer; and received payment for continuing medical education work related to psoriasis. Dr Van Voorhees served on advisory boards for Amgen, AbbVie, Celgene, Warner Chilcott, LEO Pharma, Janssen Biologics, Novartis, and Pfizer; served as an investigator for Amgen and AbbVie, receiving grants; served as a consultant for Amgen; and receives other income from Merck. Dr Siegel is employed by the National Psoriasis Foundation. The Foundation receives unrestricted financial support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen Biotech, LEO Pharma, Novartis, Pfizer, Stiefel, a GSK Company, and Taro Pharmaceuticals. Dr Chiesa Fuxench has no financial interests to disclose. |
Vol 73 - N° 5
P. 868-870 - novembre 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?